<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043004</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40004</org_study_id>
    <secondary_id>EORTC-40004</secondary_id>
    <secondary_id>ALM-CAO-EORTC-40004</secondary_id>
    <secondary_id>NCRI-EORTC-40004</secondary_id>
    <nct_id>NCT00043004</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer</brief_title>
  <official_title>CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgruppe Lebermetastasen und Tumoren</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block tumor growth&#xD;
      in different ways. Some block the ability of tumor cells to grow and spread by blocking blood&#xD;
      flow. Others find tumor cells and help kill them or carry tumor-killing substances to them.&#xD;
      Radiofrequency ablation uses high-frequency electric current to kill tumor cells. It is not&#xD;
      yet known if chemotherapy is more effective with or without radiofrequency ablation in&#xD;
      treating liver metastases.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying combination chemotherapy, bevacizumab,&#xD;
      and radiofrequency ablation to see how well they work compared to combination chemotherapy&#xD;
      and bevacizumab alone in treating unresectable liver metastases in patients with colorectal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the 30-month overall survival rate of patients with unresectable liver&#xD;
           metastases secondary to colorectal adenocarcinoma treated with chemotherapy and&#xD;
           bevacizumab with or without radiofrequency interstitial ablation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the health economics associated with this study.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to treatment center, prior adjuvant chemotherapy for primary cancer (yes vs no),&#xD;
      prior chemotherapy for liver metastases (yes vs no), and route of randomization (before&#xD;
      surgery vs during surgery). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Within 4 weeks of randomization, patients undergo radiofrequency interstitial&#xD;
           ablation (RFA) with or without additional resection of resectable lesions. Within 8&#xD;
           weeks after RFA, patients receive chemotherapy and bevacizumab.&#xD;
&#xD;
        -  Arm II: Within 4 weeks of randomization, patients receive chemotherapy and bevacizumab.&#xD;
&#xD;
      In both arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients in both arms receive one of the following chemotherapy and bevacizumab regimens to&#xD;
      be determined by participating center:&#xD;
&#xD;
        -  Regimen A: Patients receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5&#xD;
           and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 24&#xD;
           hours on day 1 of weeks 1-6 and bevacizumab IV over 30-90 minutes on days 1 or 2, 15 or&#xD;
           16, and 29 or 30. Treatment repeats every 7 weeks for 4 courses.&#xD;
&#xD;
        -  Regimen B: Patients receive oxaliplatin IV and leucovorin calcium IV over 2 hours on day&#xD;
           1 followed by fluorouracil IV continuously over 46 hours and bevacizumab IV over 30-90&#xD;
           minutes on day 1 or 3. Treatment repeats every 15 days for 12 courses.&#xD;
&#xD;
        -  Regimen C: Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium&#xD;
           IV over 2 hours followed by fluorouracil IV continuously over 22 hours on days 1 and 2&#xD;
           and bevacizumab IV over 30-90 minutes on day 1 or 3. Treatment repeats every 15 days for&#xD;
           12 courses.&#xD;
&#xD;
      Quality of life is assessed at baseline, within 1 week after completion of RFA (arm I only),&#xD;
      within 1 week before start of chemotherapy (arm I only), at weeks 6, 12, 18, and 24 during&#xD;
      chemotherapy, every 3 months for 2 years after treatment, and then every 6 months thereafter.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2Â½ years and&#xD;
      then every 6 months thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 152 patients (71 per treatment arm) will be accrued for this&#xD;
      study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate as measured by Kaplan Meier method at 30 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank every 3 months for 30 months then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival as measured by Logrank every 3 months for 30 months then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTC version 2.0 every 3 months for 30 months then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) version 3.0 at baseline, weeks 6, 12, 18, and 24, every 3 months for years 1-2 after start of treatment, then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment (arm II) as measured by RECIST criteria from start of treatment until disease progression</measure>
  </secondary_outcome>
  <enrollment type="Actual">119</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Unresectable liver metastases secondary to colorectal adenocarcinoma, including:&#xD;
&#xD;
               -  Metastases that cannot be radically resected due to size, location, or number of&#xD;
                  deposits&#xD;
&#xD;
               -  Metastases invading right and left branches of hepatic artery or portal vein&#xD;
&#xD;
               -  Metastases extended to the 3 main hepatic veins&#xD;
&#xD;
          -  No detectable extra-hepatic disease&#xD;
&#xD;
          -  Fewer than 10 metastatic deposits on liver&#xD;
&#xD;
          -  Total metastatic involvement of liver no more than 50%&#xD;
&#xD;
          -  Adequate treatment of all metastatic lesions deemed possible either by radiofrequency&#xD;
             interstitial ablation (RFA) alone or by a combination of resection of resectable&#xD;
             lesions and RFA of the remaining unresectable lesions&#xD;
&#xD;
               -  Maximum diameter of 4 cm for lesions to be treated with RFA&#xD;
&#xD;
               -  No maximum diameter of lesions to be resected as long as negative resection&#xD;
                  margins are obtainable&#xD;
&#xD;
          -  If synchronous liver metastases, must have undergone prior resection of primary tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  No bleeding disorder or coagulopathy or need for full-dose anticoagulation&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase less than 3 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2 times ULN&#xD;
&#xD;
          -  Protein &lt; 0.5 g/24 hr urine collection if proteinuria positive by dipstick&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No uncontrolled angina pectoris&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No uncontrolled arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No cerebrovascular accident or transient ischemic attack within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No greater than grade 1 peripheral neuropathy&#xD;
&#xD;
          -  No significant neurologic or psychiatric disorder&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No contraindication to the use of fluorouracil, leucovorin calcium, oxaliplatin, or&#xD;
             bevacizumab&#xD;
&#xD;
          -  No other malignancy within the past 10 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy except for metastatic disease confined to the liver&#xD;
&#xD;
               -  Prior fluorouracil, leucovorin calcium, and oxaliplatin allowed if administered&#xD;
                  for at least 3 courses (2 weeks each) but no longer than 3 months with at least&#xD;
                  stabilization of disease achieved&#xD;
&#xD;
          -  Prior adjuvant chemotherapy for primary cancer allowed except for patients who&#xD;
             received oxaliplatin and have been diagnosed with metastatic disease within 12 months&#xD;
             after completion of adjuvant treatment&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 28 days since major surgery or open biopsy past 28 days&#xD;
&#xD;
          -  More than 28 days since significant traumatic injury&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational treatment&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Ruers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolf O. Bechstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arbeitsgruppe Lebermetastasen und Tumoren</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan A. Ledermann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire De Mont-Godinne</name>
      <address>
        <city>Mont-Godinne Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute - Cairo</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Ambroise Pare - Boulogne</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen - Mitte</name>
      <address>
        <city>Essen</city>
        <zip>D-45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt am Main - Hoechst</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo-Forlanini</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis - locatie Langendijk</name>
      <address>
        <city>Breda</city>
        <zip>4800 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medical Centre - Heerlen</name>
      <address>
        <city>Heerlen</city>
        <zip>6401 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden - Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum - Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <zip>5500 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital at Gothenburg University</name>
      <address>
        <city>Gothenburg (Goteborg)</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S - 141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE 75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L69 3GA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK and University College London Cancer Trials Centre</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2ND</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal South Hants Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO14 0YG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clywd District General Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ruers T, van Coevorden F, Pierie J, et al.: Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). [Abstract] J Clin Oncol 26 (Suppl 15): A-9535, 2008.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

